Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Double-Blind, Single Dose, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)

NCT04091945 is registered in ClinicalTrials.gov with Lumosa Therapeutics Co., Ltd. as lead sponsor.

NCT NCT04091945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04091945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Double-Blind, Single Dose, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
January 27, 2020
Completion date
February 22, 2021
Enrollment
24 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke